Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr514.00 DKK
Change Today 0.00 / 0.00%
Volume 405.6K
GEN On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
OTC US
Frankfurt
As of 11:04 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Open
kr514.50
Previous Close
kr514.00
Day High
kr521.50
Day Low
kr471.00
52 Week High
04/27/15 - kr577.50
52 Week Low
05/20/14 - kr180.10
Market Cap
29.9B
Average Volume 10 Days
356.9K
EPS TTM
kr5.30
Shares Outstanding
58.1M
EX-Date
--
P/E TM
97.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. The company markets Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia. Its products under development include Ofatumumab that is in Phase III clinical studies to treat follicular lymphoma and pemphigus vulgaris; and Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, as well as Daratumumab, a CD38 monoclonal antibody that is in Phase III clinical studies to treat multiple myeloma. The company’s products under development also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for active thyroid eye disease, as well as in Phase I clinical studies for diabetic macular edema. In addition, it has approximately 20 active pre-clinical pipeline programs, including naked antibodies, immune effector function enhanced antibodies, bispecific antibodies, and ADCs. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

173 Employees
Last Reported Date: 03/2/15
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr11.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Compensation as of Fiscal Year 2014.

genmab a/s (GEN) Key Developments

Genmab A/S Announces Top-Line Results from Phase III COMPLEMENT 2 Study

Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra(r) (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p = 0.0036) compared to those given fludarabine and cyclophosphamide alone. The safety profile observed in this study was consistent with other trials of ofatumumab and no new safety signals were observed. COMPLEMENT 2 (NCT00824265) is an open-label, two-arm, randomized, Phase III study, which included 365 patients in 18 countries with relapsed CLL. Patients in the study were randomized 1:1 to treatment with up to six cycles of ofatumumab in combination with fludarabine and cyclophosphamide or up to six cycles with fludarabine and cyclophosphamide alone. The primary endpoint of the study was PFS, which was assessed by an Independent Review Committee (IRC) according to the International Workshop for Chronic Lymphocytic Leukaemia (iwCLL) updated 2008 National Cancer Institute-sponsored Working Group (NCIWG) guidelines4. Secondary endpoints included overall response rate, overall survival, patient reported outcomes, time to response, duration of response, time to progression, time to next therapy, safety assessments and quality of life. Ofatumumab is not approved for this indication and Novartis will further analyze the data from the COMPLEMENT 2 study and plans to share the results with regulatory agencies to evaluate the potential for future regulatory filings.

Genmab A/S Presents at Kempen Healthcare and Life Sciences Conference - New York, Apr-16-2015

Genmab A/S Presents at Kempen Healthcare and Life Sciences Conference - New York, Apr-16-2015 . Venue: New York, New York, United States.

Genmab A/S Announces Board Appointments

At Genmab A/S' Annual General Meeting held on March 26, 2015. At the meeting Dr. Paolo Paoletti and Pernille Erenbjerg were elected to the Board of Directors for a one year period.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr514.00 DKK 0.00

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €9.85 EUR -0.05
arGEN-X BV €9.12 EUR -0.03
MorphoSys AG €64.35 EUR -0.399
Seattle Genetics Inc $34.03 USD -0.31
XOMA Corp $3.26 USD +0.26
View Industry Companies
 

Industry Analysis

GEN

Industry Average

Valuation GEN Industry Range
Price/Earnings 90.2x
Price/Sales 31.8x
Price/Book 13.3x
Price/Cash Flow 91.6x
TEV/Sales 29.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit www.genmab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.